Comparing leukapheresis protocols for an AML patient with symptomatic leukostasis

Abigail Cline, Ryan Jajosky, James F Shikle, Roni Jacob Bollag

Research output: Contribution to journalArticle

Abstract

Background: Acute myeloid leukemia (AML) is a malignancy characterized by rapid clonal proliferation of myeloid precursors, which can result in hyperleukocytosis. Leukapheresis can be used to rapidly reduce the white blood cell count (WBC). However, the only FDA cleared device for WBC depletion, the COBE Spectra, will no longer be supported by the manufacturer in 2017, and there are few studies comparing different methods of leukapheresis. Case report: A 68-year-old African American female was admitted to the hospital for relapse of her AML. Laboratory data demonstrated a WBC count of 291 600/μL and flow cytometry of the peripheral blood demonstrated 85% myeloid blasts. Leukapheresis was ordered to help treat the leukostasis. Methods: Three different apheresis protocols were used to achieve cytoreduction: Spectra Optia mononuclear collection (MNC) protocol, Spectra Optia granulocyte collection (PMN) protocol, and Therakos CELLEX buffy coat collection without return. Due to different inlet flow rates, the procedures were evaluated based on the number of WBCs collected and volume of blood processed (VBP). Results: The Spectra Optia PMN collected the most WBCs and collected nearly as many WBCs per VBP as the Therakos CELLEX, which had the highest value. Conclusion: To our knowledge, we are reporting the first use of Therakos CELLEX and Spectra Optia PMN protocol for WBC depletion. While the Spectra Optia granulocyte protocol showed the best performance for this AML patient, further studies will be needed to compare the Spectra Optia PMN protocol to the MNC protocol for AML patients.

Original languageEnglish (US)
Pages (from-to)396-400
Number of pages5
JournalJournal of Clinical Apheresis
Volume33
Issue number3
DOIs
StatePublished - Jun 1 2018

Fingerprint

Leukostasis
Leukapheresis
Leukocyte Count
Acute Myeloid Leukemia
Blood Volume
Granulocytes
Blood Component Removal
African Americans
Flow Cytometry
Recurrence
Equipment and Supplies
Neoplasms

Keywords

  • acute myeloid leukemia
  • cytoreduction
  • hyperleukocytosis
  • leukapheresis
  • leukostasis

ASJC Scopus subject areas

  • Hematology

Cite this

Comparing leukapheresis protocols for an AML patient with symptomatic leukostasis. / Cline, Abigail; Jajosky, Ryan; Shikle, James F; Bollag, Roni Jacob.

In: Journal of Clinical Apheresis, Vol. 33, No. 3, 01.06.2018, p. 396-400.

Research output: Contribution to journalArticle

@article{5a5785f327394666af962cf064638db0,
title = "Comparing leukapheresis protocols for an AML patient with symptomatic leukostasis",
abstract = "Background: Acute myeloid leukemia (AML) is a malignancy characterized by rapid clonal proliferation of myeloid precursors, which can result in hyperleukocytosis. Leukapheresis can be used to rapidly reduce the white blood cell count (WBC). However, the only FDA cleared device for WBC depletion, the COBE Spectra, will no longer be supported by the manufacturer in 2017, and there are few studies comparing different methods of leukapheresis. Case report: A 68-year-old African American female was admitted to the hospital for relapse of her AML. Laboratory data demonstrated a WBC count of 291 600/μL and flow cytometry of the peripheral blood demonstrated 85{\%} myeloid blasts. Leukapheresis was ordered to help treat the leukostasis. Methods: Three different apheresis protocols were used to achieve cytoreduction: Spectra Optia mononuclear collection (MNC) protocol, Spectra Optia granulocyte collection (PMN) protocol, and Therakos CELLEX buffy coat collection without return. Due to different inlet flow rates, the procedures were evaluated based on the number of WBCs collected and volume of blood processed (VBP). Results: The Spectra Optia PMN collected the most WBCs and collected nearly as many WBCs per VBP as the Therakos CELLEX, which had the highest value. Conclusion: To our knowledge, we are reporting the first use of Therakos CELLEX and Spectra Optia PMN protocol for WBC depletion. While the Spectra Optia granulocyte protocol showed the best performance for this AML patient, further studies will be needed to compare the Spectra Optia PMN protocol to the MNC protocol for AML patients.",
keywords = "acute myeloid leukemia, cytoreduction, hyperleukocytosis, leukapheresis, leukostasis",
author = "Abigail Cline and Ryan Jajosky and Shikle, {James F} and Bollag, {Roni Jacob}",
year = "2018",
month = "6",
day = "1",
doi = "10.1002/jca.21588",
language = "English (US)",
volume = "33",
pages = "396--400",
journal = "Journal of Clinical Apheresis",
issn = "0733-2459",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Comparing leukapheresis protocols for an AML patient with symptomatic leukostasis

AU - Cline, Abigail

AU - Jajosky, Ryan

AU - Shikle, James F

AU - Bollag, Roni Jacob

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Background: Acute myeloid leukemia (AML) is a malignancy characterized by rapid clonal proliferation of myeloid precursors, which can result in hyperleukocytosis. Leukapheresis can be used to rapidly reduce the white blood cell count (WBC). However, the only FDA cleared device for WBC depletion, the COBE Spectra, will no longer be supported by the manufacturer in 2017, and there are few studies comparing different methods of leukapheresis. Case report: A 68-year-old African American female was admitted to the hospital for relapse of her AML. Laboratory data demonstrated a WBC count of 291 600/μL and flow cytometry of the peripheral blood demonstrated 85% myeloid blasts. Leukapheresis was ordered to help treat the leukostasis. Methods: Three different apheresis protocols were used to achieve cytoreduction: Spectra Optia mononuclear collection (MNC) protocol, Spectra Optia granulocyte collection (PMN) protocol, and Therakos CELLEX buffy coat collection without return. Due to different inlet flow rates, the procedures were evaluated based on the number of WBCs collected and volume of blood processed (VBP). Results: The Spectra Optia PMN collected the most WBCs and collected nearly as many WBCs per VBP as the Therakos CELLEX, which had the highest value. Conclusion: To our knowledge, we are reporting the first use of Therakos CELLEX and Spectra Optia PMN protocol for WBC depletion. While the Spectra Optia granulocyte protocol showed the best performance for this AML patient, further studies will be needed to compare the Spectra Optia PMN protocol to the MNC protocol for AML patients.

AB - Background: Acute myeloid leukemia (AML) is a malignancy characterized by rapid clonal proliferation of myeloid precursors, which can result in hyperleukocytosis. Leukapheresis can be used to rapidly reduce the white blood cell count (WBC). However, the only FDA cleared device for WBC depletion, the COBE Spectra, will no longer be supported by the manufacturer in 2017, and there are few studies comparing different methods of leukapheresis. Case report: A 68-year-old African American female was admitted to the hospital for relapse of her AML. Laboratory data demonstrated a WBC count of 291 600/μL and flow cytometry of the peripheral blood demonstrated 85% myeloid blasts. Leukapheresis was ordered to help treat the leukostasis. Methods: Three different apheresis protocols were used to achieve cytoreduction: Spectra Optia mononuclear collection (MNC) protocol, Spectra Optia granulocyte collection (PMN) protocol, and Therakos CELLEX buffy coat collection without return. Due to different inlet flow rates, the procedures were evaluated based on the number of WBCs collected and volume of blood processed (VBP). Results: The Spectra Optia PMN collected the most WBCs and collected nearly as many WBCs per VBP as the Therakos CELLEX, which had the highest value. Conclusion: To our knowledge, we are reporting the first use of Therakos CELLEX and Spectra Optia PMN protocol for WBC depletion. While the Spectra Optia granulocyte protocol showed the best performance for this AML patient, further studies will be needed to compare the Spectra Optia PMN protocol to the MNC protocol for AML patients.

KW - acute myeloid leukemia

KW - cytoreduction

KW - hyperleukocytosis

KW - leukapheresis

KW - leukostasis

UR - http://www.scopus.com/inward/record.url?scp=85030314674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030314674&partnerID=8YFLogxK

U2 - 10.1002/jca.21588

DO - 10.1002/jca.21588

M3 - Article

VL - 33

SP - 396

EP - 400

JO - Journal of Clinical Apheresis

JF - Journal of Clinical Apheresis

SN - 0733-2459

IS - 3

ER -